Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: A single-centre study of 163 patients

• DOI: 10.1016/j.ejso.2014.07.043
• Publication Date: 2014-09-28T13:02:49Z
• Authors: Y. Miyata; K. Nomata; K. Ohba; T. Matsuo; N. Hayashi; I. Sakamoto; M. Uetani; H. Sakai
• Keywords: Systemic therapy

Patients with muscle-invasive bladder cancer (MIBC) often undergo various preoperative treatments to improve survival; however, their efficacy and safety remain unclear.The anti-tumour effects adverse events were evaluated in 163 MIBC patients who received systemic chemotherapy (SC, n = 34), intra-arterial (IAC, 50), or combined IAC radiotherapy (IAC + R, 79).Pathological complete responses observed 17.6%, 22.0%, 43.0% of the SC, IAC, R groups, respectively, respective 5-year overall survival rates 42.0%, 46.7%, 50.3%. Multivariate analysis showed that successful protocol administration was a significant predictor for (hazard ratio 0.16, p 0.028). The incidence severe higher group (36.7%) than SC (9.8%) groups (16.0%).IAC useful MIBC. Successful completion optimal patient selection important this treatment strategy.